Swedish Orphan Biovitrum AB (publ)
F:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Swedish Orphan Biovitrum AB (publ) (B6E) under the Base Case is 41.84 EUR per share.
Compared with the current market price of 41.82 EUR, the stock appears
Fairly Valued .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Swedish Orphan Biovitrum AB Does
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs.
- Headquarters
- Sweden SE
- Employees
- 1 969
- IPO date
- Sep 15, 2006
Swedish Orphan Biovitrum has a narrow economic moat
Patents and temporary market protections on some of Sobi’s rare-disease medicines delay direct copies, helping it retain sales while rivals develop and test alternatives. Other medicines can still treat the same conditions, so these protections provide a limited barrier rather than keeping all competitors out.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
Strong portfolio growth led Sobi to raise its full-year revenue outlook, while management kept its adjusted EBITDA margin outlook unchanged.
Open the earnings call- EPS
- kr6.89
- Expected
- kr6.22
- Surprise
- +10.8%
- Stock, day of the call
- +1.1%
Past 12 months
Continue B6E Research
Decided on Swedish Orphan Biovitrum? Get an email when B6E reaches the price you’d buy at. Free with an account.
Other Swedish Orphan Biovitrum listings
What is the Intrinsic Value of one B6E stock?
The intrinsic value for
Swedish Orphan Biovitrum AB (publ) (B6E) under the Base Case is 41.84 EUR.
Is B6E stock undervalued or overvalued?
Compared with the current market price of 41.82 EUR, the stock appears Fairly Valued .